Skip to content
My WebMD Sign In, Sign Up
Font Size

Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage IV Prostate Cancer Treatment


The psychological implications of orchiectomy are objectionable to many patients, and many will choose an alternative therapy if effective.[11] Combined orchiectomy and estrogens are not indicated to be superior to either treatment administered alone.[12]

A large proportion of men experience hot flushes after bilateral orchiectomy or treatment with LH-RH agonists. These hot flushes can persist for years.[13] Varying levels of success in the management of these symptoms have been reported with DES, clonidine, cyproterone acetate, or medroxyprogesterone acetate.

After tumor progression on one form of hormonal manipulation, an objective tumor response to any other form is uncommon.[14] Some studies, however, suggest that withdrawal of flutamide (with or without aminoglutethimide administration) is associated with a decline in PSA and that one may need to monitor for this response before initiating new therapy.[15,16,17] Low-dose prednisone may palliate symptoms in about 33% of cases.[18] (Refer to the Recurrent Prostate Cancer section of this summary for more information.)

Immediate versus deferred hormonal therapy

Some patients may be asymptomatic and careful observation without further immediate therapy may be appropriate.

Evidence (immediate vs. deferred hormonal therapy):

  1. A meta-analysis of seven randomized controlled trials comparing early (adjuvant or neoadjuvant) with deferred hormonal treatment (LH-RH agonists and/or antiandrogens) in patients with locally advanced prostate cancer, whether treated with prostatectomy, radiation therapy, or watchful waiting or active surveillance, showed improved overall mortality with early treatment (relative risk, 0.86; 95% CI, 0.82–0.91).[19][Level of evidence: 1iiA]
  2. In a small, randomized trial of 98 men who underwent radical prostatectomy plus pelvic lymphadenectomy and were found to have nodal metastases (stage T1–2, N1, M0), immediate continuous hormonal therapy with the LH-RH agonist goserelin or with orchiectomy was compared with deferred therapy until documentation of disease progression.[20][Level of evidence: 1iA]; [21]
    • After a median follow-up of 11.9 years, both OS (P = .04) and prostate cancer–specific survival (P = .004) were superior in the immediate adjuvant therapy arm.
    • At 10 years, the survival rate in the immediate therapy arm was about 80% versus about 60% in the deferred therapy arm.[22]
  3. Another trial (RTOG-8531) with twice as many randomly assigned patients showed no difference in OS with early versus late hormonal manipulation.[23]
  4. Immediate hormonal therapy with goserelin or orchiectomy has also been compared with deferred hormonal therapy for clinical disease progression in a randomized trial (EORTC-30846) of men with regional lymph node involvement but no clinical evidence of metastases (any T, N+, M0). None of the 234 men had a prostatectomy or prostatic radiation therapy.[24][Level of evidence; 1iiA]
    • After a median follow-up of 8.7 years, the HR for OS in the deferred versus immediate hormonal therapy arms was 1.23 (95% CI, 0.88–1.71).
    • No statistically significant difference in OS between deferred and immediate hormonal therapy was found, but the trial was underpowered to detect small or modest differences.
  5. Immediate hormonal treatment (e.g., orchiectomy or LH-RH analog) versus deferred treatment (e.g., watchful waiting with hormonal therapy at progression) was examined in a randomized study in men with locally advanced or asymptomatic metastatic prostate cancer.[25][Level of evidence: 1iiA]
    • The initial results showed better OS and prostate cancer-specific survival with immediate treatment.
    • The incidence of pathologic fractures, spinal cord compression, and ureteric obstruction were also lower in the immediate treatment arm.
  6. In another trial, 197 men with stage III or stage IV prostate cancer were randomly assigned to have a bilateral orchiectomy at diagnosis or at the time of symptomatic progression (or at the time of new metastases that were deemed likely to cause symptoms).[26][Level of evidence: 1iiA]
    • Over a 12-year period of follow-up, no statistically significant difference was observed in OS.

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

Prostate Cancer Overview
what is your cancer risk
woman speaking with doctor
Prostate Nerve Transplant
cancer fighting foods
15 Cancer Symptoms Men Ignore
Prostate Enlarged
Picture Of The Prostate
Prostate Cancer Quiz
screening tests for men
Prostate Cancer Symptoms
Vitamin D